Colinz Laboratories Ltd

Colinz Laboratories Ltd – Closure of Trading Window

AGM Details

• Date: 22 September 2026; mode: VC/OAVM; AGM concluded at 2:48 PM IST.

Resolutions

• Resolution 1 (Ord): Adopt audited financials for FY ended; passed.
• Resolution 2 (Ord): Rotate appointment of director; passed.
• Resolution 3 (Ord): Appoint Vijaya Mani as Director (Non-Executive Non-Independent); passed.
• Resolution 4 (Special): Reappoint N. K. Menon as WTD & CEO with remuneration; passed.

Dividend

• No dividend proposed or declared.

Director Changes

• Vijaya Mani appointed as Director; N. K. Menon reappointed as Whole Time Director & CEO.

Auditors

• No change in statutory auditor; no secretarial or cost auditor changes.

Material Related Party Transactions

• No material related party transactions disclosed.

Other Material Approvals

• CEO remuneration approved; no ESOPs disclosed.

AGM details

• 40th AGM held on 22 September 2026 at 14:30 IST via Video Conferencing (OAVM).
• Chairperson Vijaya Mani chaired; quorum confirmed; founder Dr. Mani L.S. noted as deceased.

Resolutions

• Adoption of Audited Financial Statements for year ended 31 March 2026.
• Appointment/re-appointment by rotation: N.K. Menon.
• Appoint Vijaya Mani as Director (Non-Executive, Non-Independent).
• Re-appointment of N.K. Menon as Whole-Time Director and CEO with remuneration.

Voting status

• Voting results to be reconciled; Scrutinizer report within 48 hours.

Other notes

• Founder Director Dr. Mani L.S. passed away during the year.

Financial performance

• Total income Rs 662.05 Lacs; down from Rs 682.56 Lacs.
• Revenue from operations Rs 613.61 Lacs; other income Rs 48.44 Lacs.
• Profit before tax Rs 68.91 Lacs; tax expense Rs 17.46 Lacs; PAT Rs 51.45 Lacs.
• Total comprehensive income after OCI Rs 56.87 Lacs.
• EPS Rs 2.04 (basic and diluted).
• Dividend for FY2025-26 not declared.
• Net worth Rs 1004.31 Lacs; paid-up equity Rs 251.91 Lacs.
• Factory sale of Nasik plant for ₹4 Crores.
• Open Offer triggered for 34.56% promoter stake; process ongoing.

Capital structure & liquidity

• Borrowings: current Rs 38.99 Lacs; no long-term borrowings.
• Current ratio 4.63x.
• Debt-Equity ratio 0.04x.
• Net cash from operating activities Rs 254.11 Lacs.
• Cash and cash equivalents end year Rs 852.91 Lacs.
• Shareholding distribution: Promoter 49.56%; Promoter Group 16.45%; Public 32.32%.

Operations & developments

• Nasik factory sold for ₹4 Crores; sale completed June 18, 2026.
• Sale proceeds to be recognised per applicable accounting standards.
• Production now on third-party/loan license basis.
• Single segment; MSME engaged in off-patented products with long shelf life.

Governance & oversight

• Vijaya Mani appointed Additional Director on 11 Nov 2025.
• N. K. Menon re-appointed WTD/CEO for 2026-27.
• Ms. Falguni Kumawat appointed Company Secretary from 1 Dec 2025.
• Board: 8 meetings; Audit Committee: 6 meetings; Independent Directors meetings held.
• Nomination & Remuneration Committee met 5 times.

Dividends & capital allocation

• Dividend for FY2025-26 not declared.
• No equity issues or buybacks in the year.
• Promoter Open Offer for 34.56% stake; ongoing.

Shareholder information & AGM

• 40th AGM on 22 Sep 2026 at 2:30 PM via VC/OAVM.
• Remote e-voting window: 19-21 Sep 2026; cutoff 15 Sep 2026.
• Notice and AR on company website; NSDL e-voting portal.
• Registrar & Transfer Agent: Bigshare Services.

Audits & compliance

• Statutory auditors: M/s Vora & Associates; appointment until 41st AGM.
• No auditors' qualifications or fraud reported.
• Secretarial audit by Sanjay Dholakia; Annexure A attached.

Book closure & AGM details

• Book closure: 15 September 2026 to 22 September 2026 (inclusive) for the AGM.
• AGM date: 22 September 2026, held via VC/OAVM.
• E-voting window: 19 September 2026 9:00 IST to 21 September 2026 17:00 IST; cut-off 15 September 2026.
• Security: Equity shares of Colinz Laboratories Ltd.

AGM Details

• AGM date/time: 22 September 2026 at 2:30 PM IST via VC/OAVM.
• Venue deemed at registered office; proceedings via VC/OAVM.
• Register closed 15-22 September 2026; cut-off for remote e-voting 15 September 2026.

Ordinary Business

• Item 1: Adopt audited financial statements, directors' report, and auditors' report.
• Item 2: Re-appointment of Mr. N. K. Menon as Director, retiring by rotation.

Special Business

• Item 3: Appoint Mrs. Vijaya Mani as Non-Executive promoter director, liable to rotate.
• Item 4: Re-appoint Mr. N. K. Menon as WTD & CEO for one year with remuneration.

Remuneration Details

• Salary range: 7.5–12.5 LPA; allowances 7.5 LPA; gratuity up to 15 days.
• Term: 1 Oct 2026 to 30 Sep 2027; retirement by rotation.

Open Offer Overview

• Acquirers: three entities; PAC: one person.
• Target company: Target Company.
• Trigger: open offer under SEBI SAST for substantial acquisition.

Offer Details

• Shares to be acquired: a fixed number representing a material stake.
• Offer price: per-share cash offer; total consideration disclosed.
• Mode of payment: cash.
• Type of offer: open offer under SEBI SAST; triggered by substantial acquisition.

Transaction Background

• Regulatory trigger: SEBI SAST-based substantial acquisition.
• No other background transactions disclosed in this chunk.

Timeline and Eligibility

• Reminder advertisement published in August 2026.
• Eligible: public shareholders of the target.

Regulatory/Other Information

• Regulatory framework: SEBI SAST compliance required.

Open Offer Overview

• Acquirers: Annjana Dugar, Likhitta Dugar, Antariksh Dugar.
• PAC: Padam Dugar.
• Target: Colinz Laboratories Limited.
• Open offer to acquire up to 6,54,966 equity shares for cash at ₹54 per share.
• Total consideration up to ₹3,53,68,164.
• Represents 26% of voting share capital.
• Regulatory basis: SEBI SAST Regulations, 2011.

Offer Details

• Up to 6,54,966 equity shares.
• Offer price: ₹54 per share.
• Total consideration: ₹3,53,68,164.
• Mode of payment: cash.
• Type of offer: Open offer under SEBI SAST Regulations.

Transaction Background

• Open offer triggered by Public Announcement and Corrigendum dated Aug 5, 2026.
• Manager to the Offer: Saffron Capital Advisors Private Limited.
• Regulatory framework: SEBI (SAST) Regulations, 2011.

Timeline and Process

• Offer opening announced Aug 06, 2026.
• Eligible participants: Public shareholders of Colinz Laboratories Limited.

Regulatory/Other Information

• Regulatory approvals: SEBI SAST Regulations compliance.